Unlocking The Potential of Ubiquitin-Conjugating Enzyme E2 (G7324)

Target Name: UBE2E1

NCBI ID: G7324

UBE2E1

Unlocking The Potential of Ubiquitin-Conjugating Enzyme E2

Ubiquitin-conjugating enzyme E2 (ISOform 1) is a protein that plays a crucial role in the regulation of protein degradation in the cell. It is a member of the superfamily of proteins known as the ubiquitin-proteasome system (UPS), which is responsible for breaking down and clearing damaged or unnecessary proteins. E2 is one of the key enzymes in this system, and its activity is essential for the proper functioning of the UPS.

E2 is a monoclonal antibody that was identified as a potential drug target in the study of cancer. Its unique mechanism of action, as well as its potential as a drug, have made it an attractive target for researchers.

The UPS is a complex protein that consists of multiple subunits that work together to carry out the task of protein degradation. The E2 protein is a key subunit of the UPS, and it plays a crucial role in the regulation of protein degradation.

E2 is composed of 215 amino acid residues and has a calculated molecular mass of 23.9 kDa. It has a unique structure that is composed of a catalytic active site, a regulatory domain, and a catalytic domain.

The catalytic active site is the site where E2 catalyzes the formation of a covalent bond between the amino acid residue 15 and the carbon atom of amino acid residue 19. This bond formation is a critical step in the regulation of protein degradation, and E2 is the enzyme that initiates this process.

The regulatory domain is the part of the protein that interacts with other proteins to regulate its activity. This domain is composed of a N-terminal alpha-helix, a central beta-sheet, and a C-terminal hypervariable region.

The catalytic domain is the part of the protein that is responsible for the actual protein degradation. It consists of a parallel alpha-helical structure that contains a series of conserved structural features, such as a zinc atom, a carboxyl group, and a tyrosine residue.

E2 has been shown to play a critical role in the regulation of protein degradation in a variety of cell types. For example, studies have shown that overexpression of the E2 gene has been associated with the development of cancer. This is because increased levels of E2 can lead to the accumulation of damaged or unnecessary proteins, which can contribute to the development and progression of cancer.

In addition to its potential as a drug target, E2 has also been shown to have potential as a biomarker. The UPS is a well-established biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By targeting the E2 protein, researchers may be able to develop new diagnostic tests or therapeutic treatments for these conditions.

E2 has also been shown to have potential as a therapeutic target. Its unique mechanism of action, as well as its potential as a drug, have made it an attractive target for researchers.

The ability of E2 to target specific proteins is due to its unique structure and its ability to interact with other proteins. This interaction between E2 and its target proteins allows E2 to regulate the activity of these proteins and to play a role in the regulation of protein degradation.

In conclusion, Ubiquitin-conjugating enzyme E2 (ISOform 1) is a protein that plays a crucial role in the regulation of protein degradation in the cell. Its unique structure and its ability to interact with other proteins make it an attractive target for researchers. potential as a drug target and as a biomarker make it an attractive target for the development of new diagnostic tests and therapeutic treatments for a variety of diseases.

Protein Name: Ubiquitin Conjugating Enzyme E2 E1

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes the covalent attachment of ISG15 to other proteins. Mediates the selective degradation of short-lived and abnormal proteins. In vitro also catalyzes 'Lys-48'-linked polyubiquitination

The "UBE2E1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2E1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets